Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High …
P Urban, R Mehran, R Colleran, DJ Angiolillo… - Circulation, 2019 - Am Heart Assoc
Identification and management of patients at high bleeding risk undergoing percutaneous
coronary intervention are of major importance, but a lack of standardization in defining this …
coronary intervention are of major importance, but a lack of standardization in defining this …
Thrombosis and bleeding in extracorporeal membrane oxygenation (ECMO) without anticoagulation: a systematic review
Extracorporeal membrane oxygenation (ECMO) causes both thrombosis and bleeding.
Major society guidelines recommend continuous, systemic anticoagulation to prevent …
Major society guidelines recommend continuous, systemic anticoagulation to prevent …
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre …
E Ramacciotti, LB Agati, D Calderaro, VCR Aguiar… - The Lancet, 2022 - thelancet.com
Background Patients hospitalised with COVID-19 are at risk for thrombotic events after
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …
discharge; the role of extended thromboprophylaxis in this population is unknown. Methods …
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label …
RD Lopes, RHM Furtado, AVS Macedo, B Bronhara… - The Lancet, 2021 - thelancet.com
Background COVID-19 is associated with a prothrombotic state leading to adverse clinical
outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised …
outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised …
Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial
Importance Acutely ill inpatients with COVID-19 typically receive antithrombotic therapy,
although the risks and benefits of this intervention among outpatients with COVID-19 have …
although the risks and benefits of this intervention among outpatients with COVID-19 have …
[HTML][HTML] ISTH guidelines for antithrombotic treatment in COVID‐19
S Schulman, M Sholzberg, AC Spyropoulos… - Journal of Thrombosis …, 2022 - Elsevier
Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …
Postdischarge thrombosis and hemorrhage in patients with COVID-19
Abstract Coronavirus disease 2019 (COVID-19) is associated with a prothrombotic state with
a high incidence of thrombotic events during hospitalization; however, data examining rates …
a high incidence of thrombotic events during hospitalization; however, data examining rates …
[HTML][HTML] Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
RD McBane II, WE Wysokinski… - Journal of thrombosis …, 2020 - Elsevier
Background Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐
associated venous thromboembolism (VTE). While apixaban is approved for the treatment of …
associated venous thromboembolism (VTE). While apixaban is approved for the treatment of …
[HTML][HTML] Ticagrelor with or without aspirin in high-risk patients after PCI
Background Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …
therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary …
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
F Moik, WSE Chan, S Wiedemann… - Blood, The Journal …, 2021 - ashpublications.org
The risk of venous thromboembolism (VTE) and arterial thromboembolism (ATE) associated
with immune checkpoint inhibitors is currently unclear. Our aim was to quantify the risk of …
with immune checkpoint inhibitors is currently unclear. Our aim was to quantify the risk of …